3816 - Atomoxetine

Material & Volume
  • Serum, 1ml
Reference values
Age Sex Pregnant Range Unit
All No 200-1000 1-1.5h after intake
>2000 toxic
Clinical Information

Type of drug: Drug for treating ADHD
Metabolism: CYP2C19, CYP2D6, P-gp(ABCB1)
Half life t½: 2-5h
Steady State: 1day
TDM: useful
Additional Informations: Half life t½ in PM CYP2D6: 21h

Atomexetin is an effective ingredient of the ‘NARI’ group (selective noradrenalin re-uptake inhibitors) for the therapy of ‘ADHS’ and ‘ADS’. The agent selectively inhibits the ‘NET’ presynaptic noradrenalin transporter, thus enhancing the concentration of noradrenalin in the central nervous system. The resulting therapeutic effect is a significant improvement of the core syndrome in cases of ‘ADHS’ – attention deficit, impulsiveness and hyperactivity. The morst frequent side effects among children and juveniles are loss of appetite, nausea, abdominal discomfort, rise in blood pressure and solemnity.

More information
Product names
Analyses groups
  • Strattera®
Position / Price
Position: 1579.00
Price: CHF 140.00
+ Processing fee:
(per order and per day)
CHF 24.00
  • LC-MS
Executing laboratory
labor team w ag
Blumeneggstrasse 55
9403 Goldach
Execution time
1 day
During opening-hours:
Outside opening-hours: